Scott Wassel

Only 5% of people are success-minded. Which side are you on? Napoleon Hill’s words in Outwitting the Devil hit hard: “Ninety-five percent of the population are 'drifters' and only five percent are 'success-minded.'” Drifters let life dictate their direction, moving from one thing to the next without a clear purpose. They wait for circumstances to change rather than creating the change themselves. On the other hand, success-minded individuals define their own path. They have a vision, set clear goals, and don’t let external factors steer them off course. They actively pursue what they want with purpose, focus, and determination. Are you letting life lead you, or are you taking control? Drop a 🔥 if you’re ready to be part of the 5% who create their success! #MindsetMatters #SuccessMindset #NapoleonHill #PurposeDriven #LeadershipJourney

1

1 Comment

With the ever expanding base of knowledge and data in general hitting those in industry management positions, it is difficult not to become overwhelmed. How do you remain on top of issues and how do you solve problems quickly in this type of environment. This is the question most executives want answered. With AI affecting most industries and tech in particular, the information being generated is flooding the capabilities of those charged with providing effective progress. So, how do we address these concerns. This requires a different approach that takes us away from the linear thinking we've been used to and into the realm of vertical thinking. Vertical thinking requires a diffrent skill set that expands our approach to performance atainment. It requires that we build a mindset that faces change as a thing to get excited about rather than feared, so that we free up our minds in a more imaginative way. It requires us to adopt a Moonshot philosophy that assumes anything is possible and this becomes enabling as an approach to defining new potential. Adopting this type of approach attacks our limiting beliefs head on rather than allowing fear to take over. This is critical in an AI world. In an AI world, how we interface with this technology and understand our respective roles will define the new success which is possible. If we fight it rather than embracing the advantages it can offer, we will have missed the boat. However, AI will not think as "off the wall" creatively as we humans, because it is a learned capability, so putting ego aside, this should empower us to develop new leadership traits rather than be scared of this amazing opportunity. In my view we all have a part to play and it's up to us to realize where our human contribution is best felt as we emerge with a new role alongside this powerful technology. Thoughts? #vertical thinking #AI interfacing philosophy #Leadership #Human contribution # Performance leadership

1

1 Comment

📟 Back When "Wireless Communication" Meant a Beeper... Spot the guy who thought he was super cool because he had a pager! (Spoiler alert: It was me, circa 1990s, rocking that "I'm clearly very important" beeper clip on my Z Cavaricci pants) Hey Millennials - gather 'round while I tell you about ancient tech history! Before your smartphones, we had these magical devices called "pagers" that would display... wait for it... PHONE NUMBERS. That's it. Just numbers. Then we had to find a payphone (Google it) to call back. Mind-blowing, right? Join for Industry Insights Episode 4 on "The Trojan Pager: Supply Chain Security and How MES will Save the World" Key Takeaways: ·      See how far we've come from "007" meaning "I love you" in pager code ·      Learn why even "simple" tech isn't always secure ·      Discover how modern MES platforms help protect today's complex supply chains ·      Explore how cloud-based solutions beat running to payphones Because while my pager days might be history, supply chain security is definitely the future! Learn how to keep your supply chain safer than a 90’s hairstyle near an open flame. 🔗 Watch now: https://lnkd.in/gAqVAZEg No pagers or payphones required to watch this episode! 😉 #TrojanPager #SupplyChainSecurity #MES #IndustryInsights #ApprenticeIO #ThrowbackThursday

10

3 Comments

As we approach the end of 2024, it's a perfect time to reflect on the remarkable growth we've experienced this year. Shared from Barry Patel, Pharm.D is a message from our Co-Founders, Barry & Wade, on the Galt Journey; a journey of resilience, innovation, and determination. Full article can be found at the link below. https://lnkd.in/d3dVTFXH

5

1 Comment

As we approach the end of 2024, it's a perfect time to reflect on the remarkable growth we've experienced this year. Shared from Barry Patel, Pharm.D is a message from our Co-Founders, Barry & Wade, on the Galt Journey; a journey of resilience, innovation, and determination. Full article can be found at the link below. https://lnkd.in/djHdgz5z

3

Are you interested in learning more about #QPS #bioanalysis capabilities? Get an inside look at the QPS laboratories in this short video. To learn more, visit https://shorturl.at/asPrS or email [email protected]. 

7

Check out AscellaHealth’s Q2 Specialty & Rare Pipeline Digest featuring the latest updates on recent specialty drug approvals, upcoming reviews, CGT and biosimilar pipelines. If you haven’t already, make sure to subscribe today: https://lnkd.in/epMupw4w #specialtypharmacy #pharmaceuticals #raredisease #FollowAscellaHealth 

2

More than 700 biologic therapies (including biosimilars) have been approved for use by the FDA. We review the growth of the biologics market and what it means for cold storage needs in U.S. pharmacies. https://hubs.ly/Q02Yx4sm0

4

Check our our latest study that compares 340B program growth relative to the vulnerable population changes...

8

BMS is poised to enter the Eosinophilic Esophagitis (EoE) market. Buried in the BMS Q2 2024 earnings call was news that company's eosinophilic esophagitis (EoE) treatment, cendakimab, successfully met Phase 3 clinical endpoints. Similar to already-approved, Dupixent, cendakimab is a biologic with subcutaneous injections every other week. Specifics on the data have yet to be released, this new agent could pose some competitive pressure for Dupixent in EoE. #gastroenterology #clinicaldata https://lnkd.in/g_2a2MWv

9

This would be a great opportunity to get a jump on your Clinical Trial planning. If your planning or even just thinking about a trial in 2025, it is not too early to talk to potential Clinical Trial CRO partners. All we do at Translational Drug Development (TD2) is Oncology. Parris is your goto to learn about the TD2 difference. Curious what that is? Stop by and talk with Parris! #oncology #clinicaltrial #cro #clinicalcro #oncologytrial #oncologycro #cancertherapeuticdevelopment

1

How do you choose your OTC medications? With a side of mold? Made by barefoot workers? 🤮 An informative (and enraging) article detailing how a loophole that considers pharmacy chains like CVS “private-label distributors" has created an insane gap in the oversight of basic OTC medicines. With hospitals & pharmacy chains pressured to focus on driving down cost, the decision of which OTC drugs you purchase may be more important than ever. #drugsafety #OTC #pharma #retailpharmacy #hospital #generics

3

#NEW from Juliana "Julie" Reed in STAT: The PBM Monopoly intentionally forces Americans onto high-cost, high-rebate drugs. Greater use of biosimilars can save the U.S. health care system up to $133 billion by 2025. Yet these savings are being completely left on the table because PBMs prioritize high-cost, high-rebate drugs over lower-cost biosimilars. It is time we put patients first. Read the full piece below: #biosimilars #drugpricing #FTC #PBMs #patients https://lnkd.in/ePsQ7edd

35

BIG NEWS! Genezen has signed an agreement to acquire uniQure’s commercial gene therapy manufacturing operations in Lexington, Massachusetts. This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Steve Favaloro, President and Chief Executive Officer of Genezen, commented, “...This acquisition significantly enhances Genezen’s scale and differentiated capabilities, directly aligned with our mission to advance cell and gene therapies by providing top-tier, science-driven development and manufacturing solutions. We are honored to deliver these services to our current customers and the patients they serve, and are well positioned to immediately extend our support to even more customers in Lexington.” #cdmo #viralvectors #cellandgenetherapy #celltherapy #genetherapy #precisionmedicine #mergersandacquisitions #investment #finance #pharma #biotech CSL Ampersand Capital Partners https://lnkd.in/eqDDc_cf

194

15 Comments

📣 📰 Come and get it - Vol. 3 of The Pulse where we recap key findings about what sets Pittsburgh's life sciences ecosystem apart and what actions are needed to capitalize on these opportunities. https://bit.ly/pulsevol3

19

1 Comment